{"entries": [{"source": "ema", "source_id": "https://www.ema.europa.eu/en/news/ema-partners-healthcare-professionals-consumers-ittakesateam-medicine-shortages-campaign", "title": "EMA partners with healthcare professionals and consumers for #ItTakesATeam medicine shortages campaign", "abstract": "EMA, in collaboration with European healthcare professional and consumer organisations, has launched a new awareness campaign on medicine shortages. The #ItTakesATeam campaign…,         When patients can’t get a medicine in a pharmacy, their first reaction is distress. While this is legitimate, they are never alone. There are people who are there to…,   The campaign was developed jointly with the European Consumer Organisation, the European Association of Hospital Pharmacists, European Association of Nuclear Medicine, the…,         The campaign aims to showcase the coordinated system that is needed at EU level to address shortages, but it also represents a step forward in how we engage with…,   Through videos, social media messages, and stories from real people involved in addressing shortages, #ItTakesATeam puts a human face on the coordinated efforts to keep…", "url": "https://www.ema.europa.eu/en/news/ema-partners-healthcare-professionals-consumers-ittakesateam-medicine-shortages-campaign", "published_date": "2025-11-04", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-october-2025", "title": "Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 27 - 30 October 2025", "abstract": "New safety information for healthcare professionals &nbsp;Injectable tranexamic acid: serious adverse reactions when inadvertently given intrathecallyPRAC agreed on a direct…,             Agenda                                                                          Agenda of the PRAC meeting 27 - 30 October 2025Draft…,             PRAC statistics: November 2025      ,                                                                           PRAC statistics: November 2025                    English (EN) (104.68 KB - PDF)First…,             Ongoing referrals  ProcedureLevamisole-containing medicinal products,             Glossary  Safety signal assessments. A safety signal is information which suggests a new potentially causal association, or a new aspect of a known association…", "url": "https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-27-30-october-2025", "published_date": "2025-10-31", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/news/icmra-summit-2025-ema-concludes-its-two-mandates-chair", "title": "ICMRA Summit 2025: EMA concludes its two mandates as chair", "abstract": "EMA’s Executive Director, Emer Cooke, has handed over the role of chair of the International Coalition of Medicines Regulatory Authorities (ICMRA) to Anthony Lawler from the…,         “ICMRA has proven its value both as a platform for sharing information and best practices and as a venue for providing strategic leadership, active exchange of…,   At the ICMRA Summit 2025, international medicines authorities addressed the regulators’ role as communicators of reliable, evidence-based, scientific information and the…", "url": "https://www.ema.europa.eu/en/news/icmra-summit-2025-ema-concludes-its-two-mandates-chair", "published_date": "2025-10-24", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/news/ema-partners-content-creators-promote-safe-responsible-use-glp-1-medicines", "title": "EMA partners with content creators to promote safe and responsible use of GLP-1 medicines", "abstract": "EMA has launched its first social media campaign working with content creators. The #HealthNotHype campaign aims to raise awareness about the safe and responsible use of GLP-1…,         “#HealthNotHype is about passing the message that GLP-1 receptor agonists are not magic solutions for weight loss. Like all medicines, they have benefits and risks and…,   Partnering with content creatorsThe Agency carefully selected content creators from seven different Member States of the European Union (EU) to ensure a balanced geographical…,   CountryChannelFollowers (on 16 October 2025)Finlandjennipuolivali39,000Germanymedicinexcare242,000Italyinfermieregianluca175,000Latviauzlabo32,800…", "url": "https://www.ema.europa.eu/en/news/ema-partners-content-creators-promote-safe-responsible-use-glp-1-medicines", "published_date": "2025-10-21", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/news/first-treatment-serious-chronic-lung-disease", "title": "First treatment for serious chronic lung disease", "abstract": "EMA has recommended granting a marketing authorisation in the European Union (EU) for Brinsupri&nbsp;(brensocatib) 25 mg tablets, for the treatment of non-cystic fibrosis…", "url": "https://www.ema.europa.eu/en/news/first-treatment-serious-chronic-lung-disease", "published_date": "2025-10-17", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-october-2025", "title": "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 October 2025", "abstract": "Two new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended two medicines for approval at its October 2025 meeting.The committee recommended…,             CHMP statistics      ,                                                                                                                                             CHMP statistics: Text…,             Positive recommendations on new medicines,       Brinsupri      International non-proprietary name (INN)  brensocatib  Marketing authorisation applicant  Insmed Netherlands B.V.  Therapeutic indication  Treatment of…,       Wayrilz      International non-proprietary name (INN)  rilzabrutinib  Marketing authorisation applicant  Sanofi B.V.  Therapeutic indication  For the treatment of…,             Negative recommendation on new medicine,       Rezurock      INN  belumosudil  Marketing authorisation applicant  Sanofi Winthrop Industrie  Therapeutic indication  Treatment of chronic graft-versus-host disease (…,             Outcome of re-examination on recommendation for new medicine,       Austedo      INN  deutetrabenazine  Marketing authorisation applicant  Teva GmbH  Therapeutic indication  Treatment of tardive dyskinesia  More information  Austedo:…,             Positive recommendations on extensions of therapeutic indications ,       Breyanzi       INN  lisocabtagene maraleucel / lisocabtagene maraleucel&nbsp;  Marketing authorisation holder  Bristol-Myers Squibb Pharma EEIG  More information…,       Cejemly      INN  sugemalimab  Marketing authorisation holder  Cstone Pharmaceuticals Ireland Limited  More information  Cejemly: pending EC decision,       Gazyvaro      INN  obinutuzumab  Marketing authorisation holder  Roche Registration GmbH  More information  Gazyvaro: pending EC decision,       Libtayo      INN  cemiplimab  Marketing authorisation holder  Regeneron Ireland Designated Activity Company (DAC)  More information  Libtayo: pending EC decision,       Paxlovid      INN  nirmatrelvir / ritonavir  Marketing authorisation holder  Pfizer Europe MA EEIG  More information  Paxlovid: pending EC decision,       Pyrukynd      INN  mitapivat  Marketing authorisation holder  Agios Netherlands B.V.  Orphan designation  This medicine was designated an orphan medicine.  More…,       Tremfya      INN  guselkumab  Marketing authorisation holder  Janssen Cilag International  More information  Tremfya: pending EC decision,       Scemblix      INN  asciminib  Market authorisation holder  Novartis Europharm Limited  More information  Scemblix: pending EC decision,             Withdrawal of initial marketing authorisation application,       Hydrocortisone Aguettant      INN  hydrocortisone  Market authorisation applicant  Laboratoire Aguettant  Therapeutic indication  Prevention of bronchopulmonary…,             Public-health recommendation,       Oxbryta       INN  voxelotor  Market authorisation applicant  Pfizer Europe MA EEIG  More information  EMA confirms suspension of sickle cell disease medicine Oxbryta, ,             Other updates                                                                          Start of Union reviews adopted during the CHMP meeting of 13-16…", "url": "https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-october-2025", "published_date": "2025-10-17", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-7-9-october-2025", "title": "Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 7-9 October 2025", "abstract": "CVMP opinions on veterinary medicinal productsThe Committee adopted by&nbsp;consensus a positive opinion for a marketing authorisation from Zoetis Belgium&nbsp;for Lenivia…", "url": "https://www.ema.europa.eu/en/news/meeting-highlights-committee-veterinary-medicinal-products-cvmp-7-9-october-2025", "published_date": "2025-10-10", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/medicines/human/EPAR/austedo", "title": "Human medicines European public assessment report (EPAR): Austedo, deutetrabenazine, Status: Opinion", "abstract": "Human medicines European public assessment report (EPAR): Austedo, deutetrabenazine, Status: Opinion", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/austedo", "published_date": "2025-10-17", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/medicines/human/EPAR/brinsupri", "title": "Human medicines European public assessment report (EPAR): Brinsupri, Brensocatib, Status: Opinion", "abstract": "Human medicines European public assessment report (EPAR): Brinsupri, Brensocatib, Status: Opinion", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/brinsupri", "published_date": "2025-10-17", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/medicines/human/EPAR/rezurock", "title": "Human medicines European public assessment report (EPAR): Rezurock, Belumosudil, Status: Opinion", "abstract": "Human medicines European public assessment report (EPAR): Rezurock, Belumosudil, Status: Opinion", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/rezurock", "published_date": "2025-10-17", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/medicines/human/EPAR/wayrilz", "title": "Human medicines European public assessment report (EPAR): Wayrilz, rilzabrutinib, Status: Opinion", "abstract": "Human medicines European public assessment report (EPAR): Wayrilz, rilzabrutinib, Status: Opinion", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/wayrilz", "published_date": "2025-10-17", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}, {"source": "ema", "source_id": "https://www.ema.europa.eu/en/medicines/human/EPAR/aplidin", "title": "Human medicines European public assessment report (EPAR): Aplidin, plitidepsin, Status: Application withdrawn", "abstract": "Human medicines European public assessment report (EPAR): Aplidin, plitidepsin, Status: Application withdrawn", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/aplidin", "published_date": "2025-10-06", "authors": null, "journal_or_venue": "EMA", "doi": null, "disease": ["endometriosis"], "topics": null, "trial_info": null, "geos": ["EU"], "mesh_terms": null, "license": null, "quality_score": 0.0, "hash_sha256": "", "raw_blob_uri": null, "lang": "en"}]}